AU2021236878B2 - Liquid formulations of glucagon analogues - Google Patents

Liquid formulations of glucagon analogues

Info

Publication number
AU2021236878B2
AU2021236878B2 AU2021236878A AU2021236878A AU2021236878B2 AU 2021236878 B2 AU2021236878 B2 AU 2021236878B2 AU 2021236878 A AU2021236878 A AU 2021236878A AU 2021236878 A AU2021236878 A AU 2021236878A AU 2021236878 B2 AU2021236878 B2 AU 2021236878B2
Authority
AU
Australia
Prior art keywords
formulation
hypoglycaemia
present
concentration
tris
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021236878A
Other languages
English (en)
Other versions
AU2021236878A1 (en
Inventor
Tine Elisabeth Gottschalk Bøving
Jesper Skodborg VILLADSEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zealand Pharma AS
Original Assignee
Zealand Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma AS filed Critical Zealand Pharma AS
Publication of AU2021236878A1 publication Critical patent/AU2021236878A1/en
Application granted granted Critical
Publication of AU2021236878B2 publication Critical patent/AU2021236878B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2021236878A 2020-03-16 2021-03-16 Liquid formulations of glucagon analogues Active AU2021236878B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20163408 2020-03-16
EP20163408.6 2020-03-16
PCT/EP2021/056651 WO2021185821A1 (en) 2020-03-16 2021-03-16 Liquid formulations of glucagon analogues

Publications (2)

Publication Number Publication Date
AU2021236878A1 AU2021236878A1 (en) 2022-09-29
AU2021236878B2 true AU2021236878B2 (en) 2025-09-11

Family

ID=70008261

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021236878A Active AU2021236878B2 (en) 2020-03-16 2021-03-16 Liquid formulations of glucagon analogues

Country Status (23)

Country Link
US (2) US20210283053A1 (cg-RX-API-DMAC10.html)
EP (1) EP4121003B1 (cg-RX-API-DMAC10.html)
JP (1) JP7834025B2 (cg-RX-API-DMAC10.html)
KR (1) KR102956482B1 (cg-RX-API-DMAC10.html)
CN (1) CN115279341B (cg-RX-API-DMAC10.html)
AR (1) AR121581A1 (cg-RX-API-DMAC10.html)
AU (1) AU2021236878B2 (cg-RX-API-DMAC10.html)
BR (1) BR112022018462A2 (cg-RX-API-DMAC10.html)
CA (1) CA3171184A1 (cg-RX-API-DMAC10.html)
CL (1) CL2022002472A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022014452A2 (cg-RX-API-DMAC10.html)
ES (1) ES3041327T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20251267T1 (cg-RX-API-DMAC10.html)
HU (1) HUE073401T2 (cg-RX-API-DMAC10.html)
IL (1) IL295977A (cg-RX-API-DMAC10.html)
MX (1) MX2022011227A (cg-RX-API-DMAC10.html)
PE (1) PE20230258A1 (cg-RX-API-DMAC10.html)
PH (1) PH12022552457A1 (cg-RX-API-DMAC10.html)
PL (1) PL4121003T3 (cg-RX-API-DMAC10.html)
RS (1) RS67245B1 (cg-RX-API-DMAC10.html)
TW (1) TW202200190A (cg-RX-API-DMAC10.html)
UA (1) UA129439C2 (cg-RX-API-DMAC10.html)
WO (1) WO2021185821A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL312600B2 (en) 2022-05-30 2025-12-01 Zealand Pharma As Liquid formulations of amylin analogs
WO2025056677A1 (en) 2023-09-15 2025-03-20 Zealand Pharma A/S Dasiglucagon for use in the treatment of congenital hyperinsulinism

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014016300A1 (en) * 2012-07-23 2014-01-30 Zealand Pharma A/S Glucagon analogues

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
WO2011117417A1 (en) 2010-03-26 2011-09-29 Novo Nordisk A/S Novel glucagon analogues
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
UA121874C2 (uk) 2015-02-17 2020-08-10 Елі Ліллі Енд Компані Порошкова назальна композиція для лікування гіпоглікемії
WO2017053822A1 (en) 2015-09-23 2017-03-30 Behavioral Recognition Systems, Inc. Detected object tracker for a video analytics system
GB201710822D0 (en) * 2017-07-05 2017-08-16 Zealand Pharma As Methods and medical uses relating to the treatment of hypoglycaemia
WO2019110838A1 (fr) 2017-12-07 2019-06-13 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014016300A1 (en) * 2012-07-23 2014-01-30 Zealand Pharma A/S Glucagon analogues

Also Published As

Publication number Publication date
MX2022011227A (es) 2022-10-07
CN115279341A (zh) 2022-11-01
EP4121003C0 (en) 2025-08-06
AU2021236878A1 (en) 2022-09-29
JP7834025B2 (ja) 2026-03-23
US20210283053A1 (en) 2021-09-16
HUE073401T2 (hu) 2026-01-28
HRP20251267T1 (hr) 2025-12-05
PE20230258A1 (es) 2023-02-07
KR102956482B1 (ko) 2026-04-23
BR112022018462A2 (pt) 2022-11-01
EP4121003A1 (en) 2023-01-25
TW202200190A (zh) 2022-01-01
AR121581A1 (es) 2022-06-15
WO2021185821A1 (en) 2021-09-23
CL2022002472A1 (es) 2023-02-17
PL4121003T3 (pl) 2026-02-23
JP2023518052A (ja) 2023-04-27
US20250195424A1 (en) 2025-06-19
KR20220154110A (ko) 2022-11-21
CA3171184A1 (en) 2021-09-23
ES3041327T3 (en) 2025-11-11
RS67245B1 (sr) 2025-10-31
PH12022552457A1 (en) 2023-12-11
CN115279341B (zh) 2026-03-31
NZ791927A (en) 2025-09-26
EP4121003B1 (en) 2025-08-06
UA129439C2 (uk) 2025-04-23
CO2022014452A2 (es) 2022-10-21
IL295977A (en) 2022-10-01

Similar Documents

Publication Publication Date Title
JP7531564B2 (ja) インスリン分泌性ペプチドの安定な水性非経口医薬組成物
JP5657230B2 (ja) Ｇｌｐ−１分子の投与方法
US8748376B2 (en) Stable formulations of peptides
US6358924B1 (en) GLP-1 formulations
CN104662038B (zh) 胰高血糖素类似物
US20250195424A1 (en) Liquid formulations of glucagon analogues
JP7580404B2 (ja) Ｇｌｐ１／２二重アゴニストの非経口医薬組成物
CA3114330A1 (en) Formulations of glucagon-like-peptide-2 (glp-2) analogues
EP4319798B1 (en) Liquid formulations of amylin analogues
RU2819934C1 (ru) Жидкие составы аналогов глюкагона
HK40078233A (en) Liquid formulations of glucagon analogues
HK40078233B (en) Liquid formulations of glucagon analogues
EA050539B1 (ru) Жидкие составы аналогов глюкагона
HK40104625A (en) Liquid formulations of amylin analogues
HK40104625B (en) Liquid formulations of amylin analogues
TW202607013A (zh) 一種包含ｐｓｄ－９５多肽抑制劑的醫藥組成物及其製備方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)